Navigation Links
Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
Date:9/26/2007

Presentations to illustrate wide applicability of JuvImmune and JuvaVax

product platforms

PLEASANTON, Calif., Sept. 26 /PRNewswire/ -- Juvaris BioTherapeutics, Inc. announced today six scientific presentations at the upcoming IDSA meeting on October 6, 2007. The data will cover the consistency in multiple species of JuvImmune immunostimulant and JuvaVax products being developed for HIV, influenza, hepatitis and HSV-2.

"We are pleased that the company and its collaborators are presenting a number of high quality papers at the IDSA meeting in San Diego," said Martin D. Cleary, Co-founder, Chairman and CEO of Juvaris. "We believe these presentations demonstrate the wide applicability of the Juvaris JuvImmune and JuvaVax vaccine platforms for prophylaxis and treatment of infectious disease."

About Juvaris

Juvaris BioTherapeutics was created in 2003 to develop an immunotherapeutic product platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create the JuvImmune Immunostimulant, a lipid-DNA complex, which as a single product will have utility in multiple infectious disease and cancer applications. The JuvImmune product has been shown to be at least 50-times more potent at triggering innate immune activation and interferon release than current immune stimulants.

When combined with disease-specific antigens, the technology creates JuvaVax vaccines capable of activating substantial antibody- and cell-mediated immune responses, particularly induction of cytotoxic T lymphocytes (CTL). Immunological responses elicited by the lipid-DNA complexes have been successfully demonstrated in both prophylactic and therapeutic settings in a variety of mammals including rodents, rabbits, cats, dogs and non-human primates. This platform provides the opportunity to develop many disease-specific immunotherapy products, for which there are significant unmet medical needs.

The Company recently completed a Series A financing with Kleiner Perkins Caufield & Byers as the sole investor. It plans to start two clinical studies in 2008. The first will be a prophylactic vaccine for Influenza A and the second a therapy for chronic Hepatitis C.

The Company encourages investment and partnering inquiries and can be reached at its website @ http://www.juvaris.com.

Company Contact:

Martin D. Cleary

Juvaris BioTherapeutics, Inc.

925.399.6200

mdcleary@juvaris.com


'/>"/>
SOURCE Juvaris BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... ... (NYS DFS) cybersecurity regulations have transitioned into full force and effect. ... in the state (“Covered Entities”) to conduct an annual, professional, comprehensive cybersecurity ...
(Date:9/18/2017)... ... September 18, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces Bryan Coddington ... What: Digital Transformation in Medical Device – The Journey to FDA Compliant Field ...
(Date:9/14/2017)... , ... September 14, 2017 ... ... the launch of its CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary ... translation of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio ...
(Date:9/14/2017)... ... September 14, 2017 , ... Cambridge Semantics , ... announced that its Anzo Smart Data Lake has been named a KMWorld ... solutions that help organizations succeed in surpassing their knowledge management goals. KMWorld searches ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
Breaking Biology News(10 mins):